Last updated: October 14, 2026
Cevimeline hydrochloride is a mature, low-volume generic prescription drug used primarily to treat xerostomia associated with Sjögren's syndrome. The U.S. reference product, Evoxac 30 mg capsules, received FDA approval in 2000. Its exclusivity period has ended, and generic competition has reduced pricing power. Public companies do not separately report cevimeline revenue, so the product's financial trajectory must be assessed through approval history, generic availability, reimbursement, prescription volume, and market structure rather than disclosed sales figures.
What is cevimeline hydrochloride used for?
Cevimeline hydrochloride is a muscarinic agonist that stimulates residual salivary gland function. The FDA-approved indication is treatment of symptoms of dry mouth in patients with Sjögren's syndrome.[1]
| Product attribute |
Data |
| Active ingredient |
Cevimeline hydrochloride |
| U.S. brand |
Evoxac |
| Dosage form |
30 mg capsule |
| Approved indication |
Dry-mouth symptoms associated with Sjögren's syndrome |
| Typical adult dose |
30 mg three times daily |
| Regulatory class |
Small-molecule prescription drug |
| Reference sponsor |
Daiichi Sankyo |
| U.S. application |
NDA 020989 |
| Current market structure |
Brand and generic supply |
| Biosimilar exposure |
None |
Cevimeline acts primarily at muscarinic receptors and can increase salivary secretion. Common adverse effects include sweating, nausea, diarrhea, abdominal discomfort, and visual disturbances. The prescribing information warns about cardiovascular, pulmonary, ophthalmic, and gastrointestinal risks.[1]
How large is the cevimeline hydrochloride market?
The U.S. market is commercially narrow because the approved indication is limited and the patient population is smaller than the populations for broad primary-care drugs. Demand is concentrated in Sjögren's syndrome and severe medication-related or disease-related dry-mouth treatment where clinicians select a systemic secretagogue.
The commercial market has four structural characteristics:
- Demand is medically persistent but limited in volume.
- Generic substitution places pressure on average selling prices.
- Product availability is more important than brand marketing.
- Prescribing competes with pilocarpine, nonprescription saliva substitutes, hydration measures, and dental-care products.
Sjögren's syndrome creates the core addressable population. The drug is not approved for every cause of xerostomia, although physicians may prescribe it off label. That limits the value of broad promotional investment and makes payer coverage, pharmacy stocking, and reliable generic supply more important than consumer advertising.
What is the financial trajectory for cevimeline hydrochloride?
Cevimeline's financial trajectory has followed the standard pattern for an older specialty small molecule:
| Period |
Commercial phase |
Financial effect |
| 2000 to mid-2000s |
Branded launch and market development |
Highest pricing power and exclusivity value |
| Late exclusivity period |
Anticipation of generic entry |
Declining strategic value of the brand |
| Post-generic period |
Multiple-source supply |
Lower prices and fragmented manufacturer economics |
| Current mature market |
Stable niche demand |
Volume depends on diagnosis, adherence, coverage, and supply |
Daiichi Sankyo does not publicly report Evoxac revenue as a separate product line in its consolidated financial disclosures. The product is not identified as a material standalone contributor in the company's major investor reporting. Generic manufacturers also generally do not disclose cevimeline-specific revenue because sales are immaterial at the consolidated-company level.
The economic opportunity is therefore concentrated in manufacturing efficiency and supply reliability rather than premium pricing. A supplier with an approved abbreviated new drug application, dependable active pharmaceutical ingredient sourcing, and broad wholesaler access can generate recurring revenue, but the market is unlikely to support the economics of a major branded launch.
When did cevimeline lose exclusivity?
The key U.S. exclusivity period ended after approval of the reference product and the completion of FDA regulatory protections. Evoxac was approved in 2000, and its branded exclusivity period is no longer commercially relevant.[1]
Cevimeline is now a mature generic product. Any remaining commercial protection would need to arise from a specific patent, manufacturing process, formulation, or regulatory listing rather than from the original product's market exclusivity.
FDA approval history identifies the reference NDA and subsequent generic applications. The active commercial question is not whether the original brand has exclusivity, but how many generic suppliers remain active and whether supply interruptions create temporary pricing opportunities.
What patents protect cevimeline hydrochloride?
The principal patent estate for cevimeline was directed to the compound and related pharmaceutical uses developed before the U.S. launch. Those rights have expired or are no longer capable of preserving branded market exclusivity.
| Patent category |
Current commercial relevance |
| Compound patent |
Expired; does not block generic entry |
| Original composition claims |
Expired or commercially exhausted |
| Method-of-use claims |
No known active claim that preserves broad U.S. exclusivity |
| Basic capsule formulation |
Does not provide current product-level exclusivity |
| Manufacturing process patents |
Could affect a specific supplier but would not recreate broad brand exclusivity |
| Pediatric or new-use patents |
No material current market barrier identified |
Cevimeline is a small molecule rather than a biologic. Biosimilar law does not apply. Generic applicants use the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference product.[2]
What is the Orange Book status of cevimeline?
The FDA Orange Book identifies Evoxac as the reference product for cevimeline hydrochloride capsules. The relevant dosage form is the 30 mg capsule.[2]
Orange Book-listed patents and exclusivity codes determine whether an ANDA applicant must wait, certify against listed patents, or address other regulatory protections. For a mature product such as cevimeline, the central commercial consequence is that generic applicants can enter once applicable patent and exclusivity barriers have expired or been resolved.
Orange Book status should be distinguished from product availability. A drug can have no meaningful patent barrier and still experience limited competition if few manufacturers maintain active approvals or if API and finished-dose supply is constrained.
Which companies are challenging or supplying cevimeline?
Cevimeline has been supplied through generic manufacturers rather than through a single dominant branded platform. FDA databases and commercial pharmacy listings have identified generic cevimeline products from multiple manufacturers over time, including suppliers operating through U.S. marketing-authorized entities and contract manufacturing networks.[2][3]
The market's competitive intensity depends on:
- The number of active ANDAs.
- Whether manufacturers maintain commercial distribution.
- Wholesale acquisition cost and payer reimbursement.
- Availability of 30 mg capsules.
- API sourcing and manufacturing capacity.
- Pharmacy substitution and formulary treatment.
Generic entry is not equivalent to sustained competition. Some ANDA holders retain approval but sell intermittently or withdraw from the market. In a small market, a reduction from several suppliers to one or two active suppliers can create shortages or increase net pricing without changing the patent position.
What generic entry risks exist for cevimeline?
The principal risk to the reference product is permanent generic substitution. The principal risk to generic manufacturers is limited market size.
Risk to the branded product
- Loss of prescription volume to therapeutically equivalent generics.
- Payer preference for lower-cost products.
- Reduced pharmacy willingness to stock a higher-priced brand.
- Limited ability to defend share through advertising.
- Absence of a commercially important new indication.
Risk to generic manufacturers
- Low annual prescription volume.
- Price compression after additional entrants.
- Inventory carrying costs.
- API or capsule supply interruptions.
- Reimbursement below sustainable acquisition cost.
- Market withdrawal by competitors that changes volume unpredictably.
A generic launch scenario is most likely to produce rapid substitution rather than a prolonged branded/generic coexistence period. Cevimeline has limited consumer brand recognition outside the Sjögren's syndrome treatment community.
How does cevimeline compare with pilocarpine?
Pilocarpine is the closest systemic therapeutic comparator. Salagen, the pilocarpine reference product, is approved for radiation-induced xerostomia and dry-mouth symptoms associated with Sjögren's syndrome.[4]
| Attribute |
Cevimeline |
Pilocarpine |
| Reference brand |
Evoxac |
Salagen |
| Core use |
Sjögren's-related dry mouth |
Sjögren's-related and radiation-related dry mouth |
| Common U.S. dose |
30 mg three times daily |
5 mg four times daily for Sjögren's syndrome |
| Mechanism |
Muscarinic agonist |
Muscarinic agonist |
| Generic availability |
Yes |
Yes |
| Market breadth |
Narrower |
Broader approved indication set |
| Main competitive issue |
Supply and generic pricing |
Broader clinical familiarity and indication coverage |
Pilocarpine has a larger approved-use footprint because it includes radiation-induced xerostomia. Cevimeline can be preferred when clinicians perceive differences in tolerability, dosing convenience, response, or patient experience. Neither drug has strong protection from generic competition.
What formulation patents protect cevimeline?
The commercial product is a conventional immediate-release capsule. No extended-release, transdermal, implantable, or complex delivery platform has become a major commercial category for cevimeline.
That limits formulation-based lifecycle management. A company seeking differentiated economics would need to develop a clinically meaningful alternative such as less frequent dosing, improved tolerability, or combination therapy. Such a product would require new clinical and regulatory investment in a market with a limited revenue ceiling.
A conventional 30 mg capsule is relatively difficult to defend through formulation patents because the dosage form is simple and generic substitution is straightforward once the relevant rights expire.
What patent litigation and Paragraph IV challenges affect cevimeline?
No major active U.S. patent litigation is publicly associated with a current effort to preserve broad market exclusivity for Evoxac. Cevimeline's original compound and product patents are mature, and the product is already exposed to generic competition.
Paragraph IV certifications may have been used during the historical generic approval process, but they do not create a present commercial barrier unless a valid, enforceable listed patent remains. The absence of current high-value litigation is consistent with the product's low revenue base and expired core exclusivity.
What is the FDA regulatory status of cevimeline?
Cevimeline hydrochloride remains an FDA-approved prescription drug in the United States through the reference NDA and approved generic ANDAs.[1][2]
The regulatory profile is relatively stable:
- No biologics license application is involved.
- No biosimilar pathway applies.
- Generic manufacturers use ANDAs.
- The reference indication remains narrow.
- Safety labeling includes clinically relevant contraindications and warnings.
- Regulatory risk is more likely to involve manufacturing quality, supply continuity, or labeling compliance than new patent disputes.
A manufacturer seeking entry must satisfy current FDA requirements for chemistry, manufacturing, controls, bioequivalence, facility compliance, and labeling. Approval alone does not guarantee commercial distribution.
What licensing deals affect cevimeline?
Cevimeline has not generated a visible recent licensing market comparable with high-value oncology, immunology, or rare-disease products. The original commercialization history involved Daiichi Sankyo and its predecessor corporate structure, but current public filings do not identify a material standalone licensing stream for Evoxac.
The likely commercial arrangements are ordinary generic supply, distribution, contract manufacturing, and wholesaler agreements. These arrangements can affect availability and net price but generally do not create a strategic asset value comparable with an exclusive branded license.
How strong is the cevimeline patent estate?
The patent estate is weak for current branded defense and moderate only as a historical development asset.
| Patent-strength factor |
Assessment |
| Core compound protection |
Expired |
| Current blocking patents |
No material broad barrier identified |
| Formulation differentiation |
Limited |
| Method-of-use protection |
Limited commercial relevance |
| Generic substitution resistance |
Low |
| Manufacturing complexity |
Moderate but manageable |
| Supply-chain leverage |
Potentially meaningful in a small market |
| Litigation deterrence |
Low |
The most important barrier is operational rather than legal. A company with reliable API supply, compliant manufacturing, and consistent distribution may retain share even without meaningful patent protection. That advantage is vulnerable to additional entrants and price competition.
What revenue exposure does cevimeline create for manufacturers?
For diversified pharmaceutical companies, cevimeline is unlikely to represent material consolidated revenue exposure. For a small generic manufacturer, the product can be meaningful at the portfolio level because a niche product may have less direct competition than high-volume generic drugs.
Revenue sensitivity is driven by:
- Active competitor count.
- Average prescription volume.
- Net price after rebates and discounts.
- Payer coverage.
- Shortage conditions.
- Product discontinuations.
- Manufacturing utilization.
The market can produce temporary revenue increases during competitor withdrawals or shortages, but those gains are difficult to treat as durable. A new entrant should underwrite steady-state pricing below launch pricing and assume eventual erosion if multiple suppliers remain active.
What is the outlook for cevimeline hydrochloride?
Cevimeline is likely to remain a stable niche generic with low growth and limited patent-driven upside. Demand should track the diagnosed Sjögren's syndrome population, treatment persistence, clinical preference relative to pilocarpine, and insurance coverage.
The most plausible financial scenarios are:
| Scenario |
Market outcome |
| Stable supply |
Low-growth volume with continued price erosion |
| Competitor withdrawal |
Temporary price improvement and higher share for remaining suppliers |
| New entrants |
Faster price compression and lower manufacturer margins |
| Supply disruption |
Short-term pharmacy shortages and possible price volatility |
| New formulation approval |
Potential premium pricing, but high development risk |
| Expanded indication |
Higher volume, but requires clinical and regulatory investment |
Key Takeaways
- Cevimeline hydrochloride is a mature small-molecule drug marketed primarily for Sjögren's syndrome-related dry mouth.
- Evoxac's original exclusivity has ended, and generic competition is established.
- The product has no biosimilar risk because it is not a biologic.
- Its core compound and product patent protections no longer provide a meaningful U.S. market barrier.
- Public companies do not disclose material standalone cevimeline revenue.
- Market value depends more on supply reliability, active manufacturer count, and reimbursement than on patent protection.
- Pilocarpine is the principal therapeutic comparator and has a broader approved use profile.
- The commercial outlook is stable but low growth, with temporary upside possible during supply disruptions or competitor withdrawals.
- A new formulation or expanded indication could create differentiation, but the limited market size constrains development economics.
FAQs About Cevimeline Hydrochloride Market Value and Exclusivity
Is cevimeline hydrochloride still under patent?
The original compound and product protections are mature and do not provide a current broad barrier to generic competition in the United States.
Is Evoxac still sold in the United States?
Evoxac is the reference product, while generic cevimeline hydrochloride capsules are available through approved generic suppliers. Commercial availability can vary by pharmacy and wholesaler.
Can cevimeline be substituted with pilocarpine?
Both are systemic muscarinic agonists used for dry mouth, but they are not automatically interchangeable under all state substitution rules. Clinical selection depends on indication, dosing, tolerability, and prescriber judgment.
Does cevimeline have orphan-drug exclusivity?
Cevimeline's current U.S. commercial position is not protected by an active orphan-drug exclusivity period. Its market is driven by standard prescription-drug regulation and generic competition.
Is cevimeline a commercially attractive generic?
It can be attractive as a niche portfolio product when supply is reliable and the manufacturer has efficient production. It is less attractive as a standalone investment because the market is small, generic pricing is exposed to competition, and product-level revenue is limited.
References
-
U.S. Food and Drug Administration. (2000). Evoxac (cevimeline hydrochloride) prescribing information and approval history. Drugs@FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug product listings and abbreviated new drug application records for cevimeline hydrochloride. FDA.
-
U.S. Food and Drug Administration. (1998). Salagen (pilocarpine hydrochloride) prescribing information and approval history. Drugs@FDA.
